CSL to buy Talecris for $3.1 billion
This article was originally published in Scrip
Executive Summary
Australia's CSL, the world's second largest manufacturer of plasma products, is to buy the third biggest producer in the field, Talecris Biotherapeutics, for $3.1 billion.